A new smart watch which monitors for the most dangerous kinds of epileptic seizures, known as "grand mal" or "generalised tonic-clonic" seizures, has been approved by the FDA.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.